Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
  • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

• This invention relates to heterocyclic compounds possessing pharmaceutical activity, more particularly to 1,4-dihydropyridines, processes for preparing them and pharmaceutical compositions containing them.
• this invention provides a compound of formula or a salt thereof; wherein: ⁇ and ⁇ together represent a bond and additionally when B is an electron withdrawing group ⁇ can also represent -OH and ⁇ can represent hydrogen, Ar is an optionally substituted aryl radical; R represents hydrogen or an optionally substituted alkyl or aralkyl group; R1 and R2 are the same or different and are selected from hydrogen and saturated or unsaturated, cyclic or acyclic aliphatic hydrocarbon residues optionally substituted by one or more groups selected from halogen, OH, carboxy, CN, alkoxy, alkylthio, aryloxy, alkoxycarbonyl, amino, substituted amino, and optionally substituted aryl; A represents a group of formula -XR3 wherein X is a group of formula -(CHR6) p - Y-(CHR7) q -­in which formulae: Y represents 0, -S-, NR8 or a direct bond, p
• aryl when used as a group or part of a group (e.g. aryloxy, arylalkyl) is meant any mono­valent carbocyclic or heterocyclic radical possessing aromatic character and includes groups having 5 to 10 ring atoms such as phenyl, naphthyl, pyridyl (e.g. 2-, 3- or 4-pyridyl), thienyl (e.g. 2-thienyl) furyl (e.g. 2-furyl), quinolyl (e.g. 2-, 3- or 4-quinolyl), isoquinolyl (e.g. 2,3- or 4- isoquinolyl) and benzimida­zolyl.
• phenyl, naphthyl pyridyl (e.g. 2-, 3- or 4-pyridyl)
• thienyl e.g. 2-thienyl
• furyl e.g. 2-furyl
• quinolyl e.g. 2-, 3-
• heteroatoms are nitrogen, oxygen and sulphur.
• heterocyclic aromatic rings containing two heteroatoms are imidazolyl, e.g. 1-imidazolyl, thiazolyl e.g. 5-thiazolyl and pyrimidyl e.g. 5-pyrimidyl.
• alkyl when used to signify a group or part of a group such as arylalkyl or alkyloxy means any straight or branched saturated aliphatic hydrocarbon especially those having 1 to 6 carbon atoms, e.g. 1-4 carbon atoms, or cyclic saturated aliphatic hydrocarbons especially those of 5 to 7 carbon atoms. Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, n-hexyl and cyclohexyl.
• substituents e.g. substituents commonly used in pharmaceutical chemistry, e.g. halogen (e.g. Cl,Br,F), alkyl, alkyloxy, haloalkyl (e.g. CF3), or haloalkoxy (e.g. CHF2O-, CF3CH2O-), NO2, NH2, CN, alkylamino, dialkylamino, carboxy, alkyloxycarbonyl, acyl, acylamino, aryl (e.g. phenyl) or aminoalkyl.
• substituents e.g. substituents commonly used in pharmaceutical chemistry, e.g. halogen (e.g. Cl,Br,F), alkyl, alkyloxy, haloalkyl (e.g. CF3), or haloalkoxy (e.g. CHF2O-, CF3CH2O-), NO2, NH2, CN, alkylamino, dialky
• R examples of the group R are groups as described above in connection with alkyl, aryl and arylalkyl and include hydrogen, methyl, ethyl, n-propyl, isopropyl and benzyl.
• R is hydrogen.
• the groups R1 and R2 can be independently hydrogen, or saturated or unsaturated acylic hydrocarbon chains of 1 to 6 carbon atoms, e.g. lower alkyl or alkenyl, optionally substituted by aryl of 5 to 10 ring atoms, lower alkoxy, amino, diloweralkylamino, carboxyl or lower alkoxycarbonyl.
• R1 and/or R2 are methyl, ethyl, n-propyl, isopropyl, butyl, methoxymethyl, methoxyethyl, ethoxy­methyl, ethoxyethyl, methoxypropyl, aminomethyl, 2-amino­ethyl, 3-aminopropyl, dimethylaminoethyl, 2-carboxyethyl, ethoxycarbonylmethyl.
• R1 or R2 is alkyl substituted by optionally substituted aryl (including heteroaryl) examples are benzyl, pyridylmethyl or -ethyl (e.g. 3-pyridylmethyl), imidazolylmethyl (e.g. 1-imidazolyl­methyl) or imidazolylethyl.
• R1 and/or R2 are methyl and ethyl.
• R3 can be a mono- or bi-cyclic nitrogen ring hetero­aryl radical containing 5 to 10 ring atoms.
• R3 examples are imidazolyl (e.g. 1-or 3-imidazolyl), pyridyl (e.g. 2-or 3-pyridyl), thiazolyl (e.g. 2-thiazolyl), pyrrolyl (e.g. 1-pyrrolyl) or bicyclic rings such as benzimidazolyl (e.g. 1-benzimidazolyl), quinolyl (e.g. 2- ­or 4-quinolyl), isoquinolyl (e.g. 1- or 4-isoquinolyl), imidazopyridyl (e.g. 5-imidazo[1,5-a]-pyridyl).
• Preferred values are 1-imidazolyl, 3-pyridyl and 5-imidazo[1,5-a]-­pyridyl.
• Examples of X are independently -NH; -O-; -S-; -CH2-; -CH(CH3)-; -OCH2-; -CH2O-; -(CH2)2-O-; -CH2CH(CH3)-; CH(CH3)CH2-; or a group of formula -CH2-Z-CH2-, -CH2-Z-(CH2)2-, -(CH2)2-Z-CH2- where Z is S, NH or a direct bond.
• B examples are-CN, -CHO,-CH2(OMe)2 or alkyl groups of 1 to 3 carbon atoms substituted by one or more halogen atoms such as fluorine, chlorine and/or bromine especially mono-, di or tri-fluoromethyl, mono, di- or tri-chloromethyl.
• halogen atoms such as fluorine, chlorine and/or bromine especially mono-, di or tri-fluoromethyl, mono, di- or tri-chloromethyl.
• X are -CH2-, -(CH2)2-, -CH(CH3)-, -CH2CH(CH3)-, -CH(CH3)CH2-, -CH2O-, -CH2NH- and -CH2-S-.
• B is -CH2F.
• Ar examples of Ar are groups mentioned above for the definitions of aryl and included in the preferred values are 2- and/or 3-substituted phenyl groups,e.g. 2- and/or 3-nitrophenyl; 2,3-dichlorophenyl; 2-trifluoro­methylphenyl, pentafluorophenyl, naphthyl (e.g. 1-naphthyl), pyridyl (e.g. 2-pyridyl), halopyridyl (e.g. 2-chloro­pyrid-3-yl), benzimidazolyl (e.g. 4- or 7-benzimidazolyl).
• 2- and/or 3-substituted phenyl groups e.g. 2- and/or 3-nitrophenyl
• 2,3-dichlorophenyl 2-trifluoro­methylphenyl, pentafluorophenyl, naphthyl (e.g. 1-naphthyl), pyr
• Particularly preferred compounds provided by this invention have formula Ia: wherein ⁇ , ⁇ , R, R1 and R2 have the meanings given above, R5 is H or
• R is hydrogen
• R1 are H, Me, Et n Pr or i Pr.
• R2 are Me and Et.
• R11 is hydrogen
• examples of R12 are 3-nitro, 2-trifluoromethyl.
• substituents are 2,3-dihalo, e.g. are 2,3-dichloro, 3-nitro-2-halo and 3-halo-2-nitro.
• lower denotes 1 to 6 carbon atoms.
• ⁇ and ⁇ together preferably represent a bond.
• the compounds of formula I possess pharmaceutical activity in particular antihypertensive and/or hypotensive activity when tested on warm blooded animals and hence are indicated for the treatment of high blood pressure.
• the compounds of this invention antagonise calcium movement into the cell they are also vasodilators and useful in the treatment of a variety of cardiac conditions such as heart attacks, angina pectoris, cardiac arrythmias, cardiac hypertrophy and coronary vasospasm.
• the compounds of formula I also inhibit blood platelet aggregation and inhibit throm­boxane synthetase. These latter activities in combination with their antihypertensive properties makes these compounds potentially very useful for the treatment of cardiovascular disorders, especially thrombosis.
• the blood pressures of male or female spontaneously hypertensive rats are measured in a 37°C constant temperature housing by means of a tail cuff. Rats with systolic pressures below 155mmHg are discarded. Groups of rats are dosed orally with the test substance in a suitable vehicle or with vehicle alone. Systolic pressures are recorded before dosing and at se
• Calcium antagonist activity is demonstrated by examining drug effect on the response of isolated rat portal vein to increasing calcium ion concentration in vitro.
• platelet aggregation is the initial step in thrombus formation it is considered that compounds which prevent aggregation or reduce platelet adhesiveness may inhibit the initiation of the atherosclerotic process.
• the effect of drugs on adhesiveness is measured in platelet-rich plasma containing a small amount of arachidonic acid which markedly increases aggregation in vitro and may be a physiologica1 agent for doing so in vivo .
• the actual test procedure used is described below.
• New Zealand White rabbits (2.5-3kg) are anaesthetised with an injection, via the marginal ear vein, of sodium pentobarbitone 30-40 mg/kg.
• Blood is centrifuged at 200g (1500 r.p.m.) for 10 minutes at 5°C. and the platelet rich plasma (PRP) removed.
• the platelets are then kept at room temperature in a screw topped plastic centrifuge tube for the duration of the experiment.
• a twin channel platelet aggregometer - (HU aggregometer, A.Browne Ltd, Sheffield, UK) is used. 1.0 ml aliquots of PRP are prewarmed for 5-10 minutes and stirred continuously at 1100rpm. Aggregation is induced by addition of 250 ⁇ M arachidonic acid, (8 ⁇ l volume) to the PRP samples. The aggregometer output is set at maximum and the chart recorder sensitivity is altered to give a full scale deflection to this arachidonic acid response.
• Control responses are recorded as the maximum deflection obtained after addition of 250 ⁇ M arachidonic acid.
• PRP samples are preincubated for 5 minutes with the test compounds followed by arachidonic acid addition. The maximum deflection after the addition of arachidonic acid is then recorded. All drugs are screened initially at 10 ⁇ 4M (final concentration), i.e. 10 ⁇ l of a 1 ⁇ 10 ⁇ 2M stock solution of the drug dissolved in distilled water is added to the PRP.
• Dazoxiben a thromboxane synthetase inhibitor (Randall, M.J. et al Research 23 145-162, 1981) is used as a positive control and all test components are compared with Dazoxiben.
• Compounds possessing thromboxane synthetase inhibitory activity are useful in the treatment or prevention of diseases responsive to the inhibition of thromboxane synthetase especially cardiovascular disorders such as thrombosis, atherosclerosis, cerebral ischaemic attacks; and angina pectoris; peripheral vascular diseases and migraine.
• Blood (approx. 75 ml) is obtained from an anaesthetised rabbit and centrifuged at 200g for 10 minutes to obtain platelet rich plasma (PRP). An aliquot of PRP is incubated for 10 minutes at 37°C in the presence of vehicle or drug. Platelet aggregation is induced by the addition of adenosine diphosphate and adrenaline. The tubes are incubated for 3 minutes, centrifuged at 10,000g for 3 minutes and a 50 ml aliquot of the super­natant taken for radio-immunoassay of thromboxane B2 (TxB2)
• the total incubation volume is 150 ⁇ l containing 50 ⁇ l of 3H -TxB2 (0.005 ⁇ Ci), 50 ⁇ l of sample or authentic TxB2 ranging from 5 to 300 pg per tube as standards and 50 ⁇ l of rabbit anti-sera to TxB2 (in a concentration which will bind 50% of H-TxB2).
• 1ml of dextran-coated charcoal (2.5% w/v suspension in phosphate buffer pH 7.4) is then added to the tubes which are further incubated on ice for 10 minutes.
• the samples are centrifuged at 10,000g for 10 minutes and 500 ⁇ l of the supernatant added to 5ml of scintillation cocktail. Measurement of the radioactivity in the supernatant quantifies the amount of [3H]-TxB2 bound by the antibody. The concentration of unlabelled TxB2 in the sample is then determined from a linear standard curve.
• This invention also provides processes for preparing the compounds of formula I.
• both the compounds of formula I and intermediates of analogous structure may be prepared by processes which are known or are analogous to known processes; see for example Drugs of the Future, Vol. VI, No. 7, 1981 pps 427-440.
• a first general process for preparing compounds of formula I as herein­before defined wherein B is fluoroalkyl, -CN, -CHO, -CH2OH,-CH(O lower alkyl)2 or optionally substituted phenyl with the proviso (a) that when Y is O, -S- or -NR8- then p is 1 or 2, comprises reacting corresponding compounds of formula wherein Ar, R, R1 and R2 are as defined above, and one of T1 and T2 is A, the other is B wherein A and B are as defined immediately above.
• the process is conveniently carried out by heating, e.g. at reflux, in an inert solvent preferably polar such as ethanol, toluene, dimethylformamide, isopropanol, acetonitrile.
• a second general process for preparing compounds of formula I as hereinbefore defined and subject to the proviso (a) in the first process mentioned above comprises reacting a corresponding compound of formula II as shown above with a corresponding compound of formula wherein Ar, R, R1 and R2 are as defined above, and one of T1 and T2 is A, the other is B.
• This process may conveniently be carried out by heating e.g. at reflux in an inert solvent (preferably polar) such as ethanol, acetonitrile, isopropanol, toluene or dimethylformamide.
• compounds of formula I wherein the proviso (a) above applies may be prepared by reacting a compound of formula ArCHO with corresponding compounds of formula VI and V shown below wherein Ar, R, R1 and R2 are as defined above and one of T1 and T2 is A, the other is B.
• Such a process may be carried out by heating the reactants, e.g. at reflux, in an inert solvent (preferably polar) such as ethanol, acetonitrile, isopropranol, toluene or dimethylformamide.
• Compounds of formula I may be prepared by reacting compounds of formula in which formulae B is fluoroalkyl,CN, CHO, CH2OH, CH(O lower alkyl)2 or optionally substituted phenyl; ⁇ , ⁇ ,R,R1,R2,R3,R6 and R7 are as defined above, one of Z1 and Z2 is halogen (other than fluorine when B is fluoroalkyl) or a sulphonyloxy group; the other of Z1 and Z2 is -YH or Y ⁇ as appropriate (wherein Y is as defined above) and v and w, are each 0, 1 or 2 with the proviso that (i) when v is 2 and Z2 is YH or Y ⁇ then Z1 can also represent dialkylamino, e.g. -NMe2 or a quaternary ammonium group, e.g. -NMe I ⁇ .
• formulae B is fluoroalkyl,CN, CHO, CH2OH, CH
• the reaction may be carried out in an inert solvent in the presence of base, e.g. K2CO3 or a tertiary amine, e.g. triethylamine.
• base e.g. K2CO3 or a tertiary amine, e.g. triethylamine.
• Anions of the requisite starting materials may be generated by the usual methods known in the art and reacted.
• Examples of sulphonyloxy are alkyl- ­or aralkyl- or aryl-sulphonyloxy, e.g. tosyloxy or mesyloxy.
• ⁇ is OH and/or ⁇ is -CH2OH,the hydroxy group(s) may be protected e.g. as a benzyl ether before the reaction and deprotected afterwards.
• the starting materials of formula VII wherein Z1 is halogen, sulphonyloxy as defined above may be prepared by known methods, e.g. from corresponding compounds of formula by methods known for the conversion of OH to halogen or sulphonyloxy.
• Compounds of formula VII wherein v is 2 and Z1 is -N(alkyl)2 or a quaternary ammonium group may be prepared by performing a Mannich reaction on a compound of formula using formaldehyde and secondary amine and if required reacting the product with an alkyl halide.
• Compounds of formula VII wherein Z1 is Y ⁇ may be prepared by known methods. For example, when Z1 is -OH, -NHR8 or -SH anions may be formed in the presence of a strong base, e.g. an alkali metal hydride such as NaH or BuLi. When Y is a direct bond carbanions may be prepared from the corresponding halo compound using for example, lithium diisopropylamine or BuLi.
• Compounds of formula I wherein ⁇ and ⁇ are a bond may also be prepared by dehydrating a compound of formula I wherein ⁇ represents OH and ⁇ represents hydrogen and Ar,A,B,R,R1 and R2 are as defined above.
• This process may be carried out in a solvent which is inert under the reaction conditions, e.g. CH2Cl2 and in the presence of a dehydrating agent, e.g. (CF3CO)2O, and a base, e.g. pyridine.
• the dehydration may also be effected using diethylaminosulphur trifluoride. When the latter reagent is used and B is CH2OH or CHO then these groups will be converted during the reaction to -CH2F and -CHF2 respectively.
• Compounds of formula I wherein B is -CH2F or -CHF2 and ⁇ and ⁇ are a bond may also be prepared by reacting a corresponding compound of formula I wherein B is -CHO or -CH2L where L is OH or a leaving group with a fluorinating agent such as a dialkylaminosulphur trifluoride, e.g. diethylaminosulphur trifluoride or (2-chloro-1,1,2-trifluoroethyl)diethylamine.
• a fluorinating agent such as a dialkylaminosulphur trifluoride, e.g. diethylaminosulphur trifluoride or (2-chloro-1,1,2-trifluoroethyl)diethylamine.
• L examples are organic sulphonyloxy groups such as alkyl, aralkyl- or aryl-sulphonyloxy, especially -OSO2 lower alkyl, -OSO2aryl where aryl is for example p-tolyl.
• the reaction may be carried out with heating in an inert solvent such as methylene dichloride.
• this group may be hydrolysed selectively to give a compound of formula I wherein B is -CHO.
• the hydrolysis may be carried out under aqueous acid conditions e.g. hydrochloric acid in a water miscible solvent such as acetone, with or without heating.
• Compounds of formula I wherein B is CN may be prepared by removing the elements R10OH from a compound of formula wherein Ar, R, R1, R2, A, ⁇ and ⁇ are as defined above and OR10 represents hydroxy or a leaving group, e.g. a 2,4-dinitrophenoxy group using a dehydrating agent e.g. acetic anhydride or thionyl chloride under mild conditions that will not affect other substituents in the molecule.
• a dehydrating agent e.g. acetic anhydride or thionyl chloride
• Compounds of formula I wherein R is other than hydrogen may be prepared by alkylating a compound of formula I wherein R is H in the presence of a strong base, e.g. an alkali metal hydride, with a compound of formula R - halogen where R is as defined above other than hydrogen.
• a strong base e.g. an alkali metal hydride
• the compounds of formula I possess one or more asymmetric centres and hence optical isomers and mixtures thereof are possible. All such isomers and mixtures thereof are included within the scope of this invention. Where any reaction process produces mixtures of such isomers standard resolution techniques may be applied to separate a specific isomer.
• salts include salts with pharmaceutically acceptable acids such as hydrochloric, hydrobromic, hydroiodic, sulphuric, phosphoric, nitric, acetic, citric, tartaric, fumaric, succinic, malonic, formic, maleic acid or organosulphonic acids such as methane sulphonic or p-tolyl sulphonic acids.
• pharmaceutically acceptable acids such as hydrochloric, hydrobromic, hydroiodic, sulphuric, phosphoric, nitric, acetic, citric, tartaric, fumaric, succinic, malonic, formic, maleic acid or organosulphonic acids such as methane sulphonic or p-tolyl sulphonic acids.
• salts When acidic substituents are present it is also possible to form salts with bases e.g. alkali metal (such as sodium) or ammonium salts. Such salts of the compounds of formula I are included within the scope of this invention.
• bases e.g. alkali metal (such as sodium) or ammonium salts.
• quaternary ammonium salts may be formed by quaternizing with an alkylating agent such as alkyl, or aralkyl halides.
• compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
• any suitable carrier known in the art can be used.
• the carrier may be a solid, liquid or mixture of a solid and a liquid.
• Solid form compositions include powders, tablets and capsules.
• a solid carrier can be one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, binders, or tablet disintegrating agents; it can also be encapsulating material.
• the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
• the active ingredient is mixed with a carrier having the necessary binding properties and compacted in the shape and size desired.
• the powders and tablets preferably contain from 5 to 99, preferably 10-80% of the active ingredient.
• Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax and cocoa butter.
• composition is intended to include the formulation of an active ingredient with encapsulating material as carrier, to give a capsule in which the active ingredient (with or without other carriers) is surrounded by carriers, which is thus in association with it. Similarly cachets are included.
• Sterile liquid form compositions include sterile solutions, suspensions, emulsions, syrups and elixirs.
• the active ingredient can be dissolved or suspended in a pharmaceuitcally acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both.
• a pharmaceuitcally acceptable carrier such as sterile water, sterile organic solvent or a mixture of both.
• the active ingredient can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol containing from 10 to 75% of the glycol by weight is generally suitable.
• suitable organic solvent for instance aqueous propylene glycol containing from 10 to 75% of the glycol by weight is generally suitable.
• Other compositions can be made by dispersing the finely-divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, for instance arachis oil.
• the pharmaceutical composition is in unit dosage form, the composition is sub-divided in unit doses containing appropriate quantities of the active ingredient;
• the unit dosage form can be a packaged composition, the package containing specific quantities of compositions, for example packeted powders or vials or ampoules.
• the unit dosage form can be a capsule, cachet or tablet itself, or it can be the appropriate number of any of these in packaged form.
• the quantity of active ingredient in a unit dose of composition may be varied or adjusted from 10 to 500 mg or more, e.g. 25 mg to 250 mg, according to the particular need and the activity of the active ingredient.
• the invention also includes the compounds in the absence of carrier where the compounds are in unit dosage form. Based on the results from animal studies the dosage range for the treatment of humans using a compound of formula I will be in the range from about 5 mg to 500 mg per day depending on the activity of the compound.
• Example 22 The compound of Example 22 is treated with NaBH4 in ethanol solvent to give the title compound.
• Example 11 The compound of Example 11 is dehydrated using 1:1 v/v pyridine and trifluoroacetic anhydride to give the title compound, m.p. 190-190.5°C (hydrochloride).
• the solution was concentrated to an oil which was partitioned between ether (50 ml) and 2 N hydrochloric acid (2 ⁇ 37.5 ml, then 15 ml).
• the acid phases (including a heavy oil that separated below the acid phase in the first extraction) were combined and washed with further ether (25ml), causing the crystallisation of a solid (A) which was collected and washed with ether (20ml).
• the ether phases were discarded and the filtered acid phases were extracted with chloroform (3 ⁇ 25ml).
• the combined extracts were dried (Na2SO4) and evaporated, leaving a solid (B; 0.448g).

Applications Claiming Priority (2)

Publications (3)

Family

ID=10592383

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (1)

Citations (7)

Family Cites Families (2)

• 1986
  • 1986-02-01 GB GB868602518A patent/GB8602518D0/en active Pending
• 1987
  • 1987-01-28 PT PT84206A patent/PT84206B/pt not_active IP Right Cessation
  • 1987-01-29 DE DE3751562T patent/DE3751562T2/de not_active Expired - Fee Related
  • 1987-01-29 GB GB8702016A patent/GB2185982B/en not_active Expired - Fee Related
  • 1987-01-29 EP EP87300785A patent/EP0233015B1/fr not_active Expired - Lifetime
  • 1987-01-29 ES ES87300785T patent/ES2078215T3/es not_active Expired - Lifetime
  • 1987-01-29 AT AT87300785T patent/ATE129242T1/de not_active IP Right Cessation
  • 1987-01-30 HU HU87311A patent/HU199139B/hu not_active IP Right Cessation
  • 1987-01-30 CA CA000528568A patent/CA1329600C/fr not_active Expired - Fee Related
  • 1987-01-31 KR KR1019870000771A patent/KR950003922B1/ko not_active IP Right Cessation
  • 1987-01-31 JP JP62021651A patent/JPH0723370B2/ja not_active Expired - Lifetime
• 1990
  • 1990-06-25 US US07/544,097 patent/US5064842A/en not_active Expired - Lifetime
• 1996
  • 1996-01-18 GR GR960400116T patent/GR3018729T3/el unknown

Patent Citations (7)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events